Clinical Scorecard: FDA revises warnings on 3 estradiol patches

At a Glance

Key Highlights

• FDA revised boxed warnings for Minivelle, Vivelle, and Vivelle-Dot, removing statements about cardiovascular disease, breast cancer, and probable dementia.
• The labeling changes do not eliminate underlying risks; cardiovascular and breast cancer information remains elsewhere in prescribing information.
• The boxed warning for endometrial cancer with unopposed systemic estrogen in women with a uterus remains.
• The revised Vivelle-Dot label retains contraindications including current or prior breast cancer, deep vein thrombosis, pulmonary embolism, and arterial thromboembolic disease.
• FDA reported increased estradiol patch production and no imminent nationwide shortage, while noting localized supply difficulties.

Guideline-Based Recommendations

Diagnosis

Management

• Before treatment, evaluate vascular and thromboembolic risk factors, as advised in the revised Vivelle-Dot prescribing information.
• Consider initiating therapy in women younger than 60 years or within 10 years of menopause, as advised in the revised Vivelle-Dot label.
• If a patient cannot obtain their usual patch, consult a pharmacist or health care professional about available alternatives; supply may vary by brand, strength, dosing schedule, and location.

Monitoring & Follow-up

Risks

• Removal of cardiovascular disease and breast cancer statements from boxed warnings does not establish that hormone therapy is free of these risks.
• The boxed warning for endometrial cancer associated with unopposed systemic estrogen therapy in women with a uterus remains.
• The revised Vivelle-Dot label lists current or prior breast cancer, deep vein thrombosis, pulmonary embolism, and arterial thromboembolic disease as contraindications.
• The prescribing information notes that applicability of cardiovascular findings from the WHI estrogen-alone trial of oral conjugated estrogens to other estrogen products or routes remains uncertain.

Patient & Prescribing Data

Women using or considering Minivelle, Vivelle, or Vivelle-Dot for menopausal hormone therapy.

The FDA revised labeling for these three estradiol patches. Patients having difficulty obtaining their usual patch are advised to ask a pharmacist or health care professional about alternatives; availability may differ by brand, strength, dosing schedule, and location.

Clinical Best Practices

• Use the current product-specific prescribing information when discussing risks and contraindications.
• Do not interpret removal of statements from boxed warnings as removal of the underlying risks.
• Discuss treatment timing and assess vascular and thromboembolic risk factors before treatment, consistent with the revised Vivelle-Dot label.

Related Resources & Content

• US Department of Health and Human Services announcement
• FDA Minivelle Prescribing Information
• FDA Vivelle Prescribing Information
• FDA Vivelle-Dot Prescribing Information